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Neurosteroids represent a class of endogenous steroids that are synthesized in the brain,
the adrenals, and the gonads and have potent and selective effects on the GABAA-
receptor. 3α-hydroxy A-ring reduced metabolites of progesterone, deoxycorticosterone,
and testosterone are positive modulators of GABAA-receptor in a non-genomic man-
ner. Allopregnanolone (3α-OH-5α-pregnan-20-one), 5α-androstane-3α, 17α-diol (Adiol), and
3α5α-tetrahydrodeoxycorticosterone (3α5α-THDOC) enhance the GABA-mediated Cl- cur-
rents acting on a site (or sites) distinct from the GABA, benzodiazepine, barbiturate, and
picrotoxin binding sites. 3α5α-P and 3α5α-THDOC potentiate synaptic GABAA-receptor
function and activate δ-subunit containing extrasynaptic receptors that mediate tonic
currents. On the contrary, 3β-OH pregnane steroids and pregnenolone sulfate (PS) are
GABAA-receptor antagonists and induce activation-dependent inhibition of the receptor.
The activities of neurosteroid are dependent on brain regions and types of neurons. In
addition to the slow genomic action of the parent steroids, the non-genomic, and rapid
actions of neurosteroids play a signiﬁcant role in the GABAA-receptor function and shift
in mood and memory function. This review describes molecular mechanisms underlying
neurosteroid action on the GABAA-receptor, mood changes, and cognitive functions.
Keywords: allopregnanolone, THDOC, pregnenolone sulfate, GABAA-receptor, premenstrual dysphoric disorder,
mood, cognition
NEUROSTEROID
Sex hormones act through genomic mechanisms through the
intracellular receptors located in the nucleus or cytoplasm. They
act as ligand-activated transcription factors in the regulation of
gene expression. However, metabolites of progesterone and sev-
eral stress hormones act on the membrane bound receptor via a
non-genomic mechanism. The receptor binding to DNA and RNA
synthesis is thus not required (Frye et al., 1992; Baulieu and Robel,
1995; Rupprecht, 2003). While the genomic action of sex hor-
mones requires a time period from minutes to hours and limited
by the rate of protein biosynthesis (McEwen, 1991), the modula-
tion on themembrane receptor is fast occurring event and requires
only milliseconds to seconds (McEwen, 1991). Today it is known
that metabolites of sex and stress hormones act non-genomically
Abbreviations: 3β5β-P, 3β-OH-5β-pregnan-20-one, epipregnanolone; 3β5α-P,
3β-OH-5α-pregnan-20-one, isoallopregnanolone; 3α5α-P, 3α-OH-5α-pregnan-
20-one, allopregnanolone; 3α5β-P, 3α-OH-5β-pregnan-20-one, pregnanolone;
3α5α-THDOC, 3α, 5α-tetrahydrodeoxycorticosterone; 3α5β-THDOC, 3α, 5β-
tetrahydrodeoxycorticosterone; 3β5β-THDOC, 5β-pregnan-3β, 21-diol-20-one;
3α-adiol/3α5α-ADL, 5α-androstane-3α, 17β-diol; 3β-HSD, 3β-hydroxysteroid
dehydrogenase; 3α-OH, 3α-hydroxy; 3β-OH, 3β-hydroxy; CGC, cerebellar gran-
ule cells; CNS, central nervous system; DGC, dentate gyrus granule cells; DHEAS,
dehydroepiandrosterone sulfate; DOC, deoxycorticosterone; EC50, concentration
of drug that produces 50% of maximum response; GABA, γ-amino butyric acid;
LTP, long-term potentiation; MPA, medroxyprogesterone; MPN, medial preoptic
nucleus; nAChRs, nicotinic acetylcholine receptors; NMDA,N -methyl-d-aspartate;
P45021, steroid 21 hydroxylase; P450c17, steroid 17 alpha-hydroxylase/17, 20 lyase;
PMS/PMDD, premenstrual syndrome/premenstrual dysphoric disorder; PS, preg-
nenolone sulfate; sIPSC, spontaneous inhibitory postsynaptic current; TBPS, t -butyl
bicyclophosphorothionate; UC1011, 3β, 20β-dihydroxy-5α-pregnane.
in the CNS and alter neuronal excitability (Majewska et al., 1986;
Paul and Purdy, 1992; Lambert et al., 1995).
The term “neurosteroid” was introduced to describe these
steroid metabolites that modulate neuronal activity (Paul
and Purdy, 1992; Baulieu et al., 2007; Mellon, 2007). The
3α-hydroxy A-ring reduced metabolites of progesterone and
deoxycorticosterone, allopregnanolone (3α5α-P), and 3α, 5α-
tetrahydrodeoxycorticosterone (3α5α-THDOC) were ﬁrst shown
to modulate neuronal excitability by interaction with the GABAA-
receptor (Majewska et al., 1986). Several other neurotransmit-
ters like the NMDA, nicotinic, muscarinic, serotonergic, adren-
ergic, and sigma 1 receptors are also targets for neurosteroids
(Klangkalya and Chan, 1988; Wu et al., 1991; Valera et al., 1992;
Compagnone and Mellon, 2000; Mellon et al., 2001; Parry, 2001;
Halbreich, 2003; Mellon, 2007). The functional modulation of
the GABAA-receptor by neurosteroids at low concentrations is
believed to induce moderate to severe adverse mood changes in
up to 20% of female individuals (Beauchamp et al., 2000; Fish
et al., 2001). The clinical complex of premenstrual dystrophic
disorders (PMDD; Backstrom et al., 2003; Sundstrom Poromaa
et al., 2003), petit mal epilepsy (Grunewald et al., 1992; Baner-
jee and Snead, 1998), and catamenial epilepsy (Backstrom, 1976)
are among the disorders that may involve neurosteroid action. At
higher doses, neurosteroids may affect learning (Johansson et al.,
2002), act as anxiolytic, anti-aggressive, sedative/anesthetic, and
anti-epileptic agents in both animals and humans (Backstrom
et al., 1990; Paul and Purdy, 1992; Wang et al., 2001; Bjorn et al.,
2002).
As shown in Figure 1, neurosteroids are synthesized in glial
cells and neurons of the central and peripheral nervous system
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from cholesterol or steroidal precursors imported from periph-
eral sources (Schumacher et al., 2000; Baulieu et al., 2007). They
include 3β-hydroxy-Δ5-compounds such as pregnenolone and
dehydroepiandrosterone, their sulfate esters and reduced metabo-
lites of steroid and stress hormones such as the tetrahydroderiv-
ative of progesterone, 3α-hydroxy-5α-pregnan-20-one (allopreg-
nanolone; Baulieu et al., 2007). Progesterone itself is also a neuros-
teroid, and a progesterone receptor has been detected in peripheral
and central glial cells (Schumacher et al., 2000;Baulieu et al., 2007).
At different sites in the brain, concentrations of neurosteroids vary
according to environmental and behavioral circumstances, such as
stress, sex recognition, and aggressiveness. Allopregnanolone can
accumulate in the brain after adrenalectomy and gonadectomy
(Purdy et al., 1991; Corpechot et al., 1993; Cheney et al., 1995).
This indicates that allopregnanolone is synthesized in the brain
via A-ring reduction of progesterone (Celotti et al., 1992; Do Rego
et al., 2009). Table 1 shows concentrations of major neurosteroids
in the plasma and brain.
Pregnenolone sulfate (PS) and dehydroepiandrosterone sul-
fate (DHEAS) are naturally occurring neurosteroids that inhibit
the GABAA-receptor (Paul and Purdy, 1992). PS is synthesized
from pregnenolone by the enzyme sulfotransferase (Figure 1).
Conversion from DHEA to DHEAS is also mediated by sulfotrans-
ferase. DHEA is metabolized from pregnenolone by cytochrome
P450C17 (Mensah-Nyagan et al., 1999). On the other hand, 3β-
HSD is essential for the synthesis of 3β-OH steroids, i.e., 3β-OH-
5α-pregnan-20-one (isoallopregnanolone; 3β5α-P) and 3β-OH-
5β-pregnan-20-one (epipregnanolone; 3β5β-P; Stromstedt et al.,
1993). PS, DHEAS, and 3β-OH steroids act as antagonists on the
GABAA-receptor (Wang et al., 2002; Eisenman et al., 2003) and
can be measured from human blood samples (Hill et al., 2001).
As metabolites of stress hormone deoxycorticosterone (DOC),
3α5α-THDOC and 3α5β-THDOC are also potent modulators of
the GABAA-receptor (Crawley et al., 1986; Majewska et al., 1986;
Gasior et al., 1999; Lambert et al., 2001a). Both steroids have sig-
niﬁcant sedative effects in vivo. 3α5α-THDOC is responsible for
the sedative and anti-seizure activity of DOC in animal mod-
els (Reddy and Rogawski, 2002). DOC can be metabolized from
progesterone and this conversion is mediated by P45021 (Edwards
et al., 2005). The conversion of DOC to 3α5α-THDOC occurs
both in peripheral tissues and in the brain (Reddy, 2003). The
A-ring reducedmetabolite of testosterone, 5α-androstane-3α,17β-
diol (3α5α-adiol), acts also as a GABAA-receptor agonist (Frye
et al., 1996).
GABAA-RECEPTOR
GABA mediates most of the inhibitory neurotransmission in the
mammalian brain. GABA-mediated inhibition is crucially in both
short-term and long-term regulation of neuronal excitability. It
has been estimated that approximately 33% of the synapses in the
mammalian cerebral cortex are GABAergic (Purvez et al., 2004).
Two major types of receptors, GABAA- and GABAB-receptors can
be identiﬁed in the CNS (Sivilotti and Nistri, 1991; Bormann,
2000). It appears that neurosteroids more or less exclusively tar-
get the GABAA-receptor which is a ligand gated anion-selective
channel (Schoﬁeld et al., 1987).
Various isoforms of the GABAA-receptor have been identiﬁed
that comprise α1–6, β1–3, γ1–3, δ, ε, π, θ, and ρ1–3 subunits (Amin
and Weiss, 1994; Mehta and Ticku, 1999; Rudolph et al., 2001). In
general, GABAA-receptors are pentameric proteins (Nayeem et al.,
1994) that are built of ﬁve subunits which includes twoα-subunits,
two β-subunits and one subunit of either theγ-,δ-, ε-,π-, or θ-type
(Farrar et al., 1999; Knight et al., 2000; Klausberger et al., 2001).
A subgroup of GABAA-receptor channels was named as GABAC-
receptor earlier and composed of homo-oligomeric ρ1–3 subunits.
They are pharmacologically distinct from other GABAA-receptor
channels and this difference is illustrated by the insensitivity of ρ
receptor channels tomany knownmodulators such as barbiturates
and benzodiazepine (Amin and Weiss, 1994, 1996).
Immunological, pharmacological, and functional analysis give
the evidence that the α1β2γ2 combination is the most common
GABAA-receptor within the CNS (∼60%), followed by α2β3γ2
(∼15–20%) and α3βnγ2 (∼10–15%, n = 1, 2, or 3; Mohler et al.,
2002, 2004; Fritschy and Brunig, 2003;Wallner et al., 2003). Recep-
tors containing the α4-, α5-, and α6-subnit, as well as the β1-, γ1–3,
δ-, π-, and θ-subunit, form a minor receptor population. Each of
Table 1 | Neurosteroid concentrations in human plasma and brain (mean±SEM).
Steroids Plasma (nM) Brain (nM)
Follicular Luteal Postmenopausal Luteal
Progesterone 5.0±0.50 (Wang et al., 1996) 34.7±2.40 65 (Bixo et al., 1997) 137 (Bixo et al., 1997)
3α-OH-5β-pregnan-20-one 0.6±0.00 (Sundstrom et al., 1998) 1.1±0.50 – 114 (Bixo et al., 1997)
3α-OH-5α-pregnan-20-one 0.2–0.6 (Wang et al., 1996;
Genazzani et al., 1998)
2–4 (Wang et al., 1996;
Genazzani et al., 1998)
47 (Bixo et al., 1997) 66 (Bixo et al., 1997)
3β-OH-5α-pregnan-20-one 0.3–0.5 (Wang et al., 1996;
Sundstrom et al., 1998))
1.5–3.5 (Wang et al., 1996;
Sundstrom et al., 1998)
– –
3β-OH-5β-pregnan-20-one 0.09±0.08 (Havlikova et al., 2006) 0.26±0.13 – –
Pregnenolone sulfate 11.2±0.6 (Wang et al., 1996) 15.2±0.8 (Bixo et al., 1997) – 100 (Lanthier and Pat-
wardhan, 1986)
Pregnenolone *2.19 (Kancheva et al., 2007) – – –
3α5α-androstane-3α,17β-diol *0.475 (Kancheva et al., 2007) – – –
Data cited from references are inserted as indicated. *Concentration in adult men.
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FIGURE 1 | Biosynthesis of allopregnanolone and pregnenolone
sulfate (PS) from cholesterol within the neuron or glial cell. Enzymes
involved are P450 side-chain cleavage (P450scc), 3α-hydroxysteroid
dehydrogenase (3α-HSD), 3β-hydroxysteroid dehydrogenase (3β-HSD) and
5α-reductase. Transport of cholesterol across the mitochondrial membrane
is enhanced by the steroidogenic acute-regulatory (StAR) protein and the
mitochondrial benzodiazepine receptor (MBR). 5α-DHP represents
5α-dihydroprogesterone.
the α4βnδ,α4βnγ, and the α6β2/3γ2 receptor accounts less than 5%
of all theGABAA-receptor quantity (McKernanandWhiting,1996;
Whiting, 2003a,b). The α6βnδ receptor has a small population in
the cerebellum and the α6β2/3γ2 receptor located exclusively in the
cerebellum (McKernan and Whiting, 1996; Whiting, 2003a,b).
The expression of GABAA-receptor subtypes in the adult brain
exhibits a remarkable regional and neuronal speciﬁcity which sug-
gests that individual subtypes are present in distinct neuronal
circuits. The α1β2γ2 receptor is present in most brain areas and
it is localized to interneurons in the hippocampus and cortex
(layer I–IV), and cerebral Purkinje cells (McKernan and Whiting,
1996). The α2β3γ2 receptor is present in cerebral cortex (layer I–
IV), hippocampal formation, amygdale, striatum, olfactory bulb,
hypothalamus, superior colliculi, and motor nuclei (Fritschy and
Brunig, 2003). The α3βnγ2, α3γ2, and α3θ receptors are abun-
dant in the cerebral cortex (layersV–VI), amygdala, olfactory bulb,
thalamic reticular and intralaminar nuclei, superior colliculus,
brainstem, spinal cord, and locus coeruleus. The α4βnδ (n = 1, 2,
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or 3) receptor is presented in the dentate gyrus and thalamus. The
α5β3γ2 receptor is widespread in the hippocampus and dentate
gyrus (Glykys et al., 2008), deep cortical layers, amygdala, olfactory
bulb, hypothalamus, superior colliculus, superior olivary nucleus,
spinal trigeminal nucleus, and spinal cord. The α6β2/3γ2, α6β2/3δ,
and α6β2/3γ2 receptors are found mainly in the cerebellum and
dorsal cochlear nucleus (Fritschy and Brunig, 2003).
PHARMACOLOGICAL RELEVANCE OF GABAA-RECEPTOR SUBUNIT
COMPOSITIONS
Especially the different α-subunits have been attributed to spe-
ciﬁc behavioral effects as shown in Table 2. For example, an
enhancement at the α1 subunit has been associated with seda-
tion (Rudolph et al., 1999) and the α2 with anxiolytic action.
Recently, it has been shown that the α5 subunit is important
for sedative tolerance development to benzodiazepines and for
acquisition and expression of associative memory and spatial
learning (Collinson et al., 2002; Crestani et al., 2002; van Rijn-
soever et al., 2004; Yee et al., 2004). In addition, the α4 subunit
is also implicated in the regulation of anxiety (Gulinello et al.,
2001). A concentration-dependent decrease of the α4 subunit is
seen after 4-day application of allopregnanolone to developing
neuronal cells (Grobin and Morrow, 2000). In the hippocampus
and cerebellum, an increase of the α4 subunit can be detected after
withdrawal from chronic exposure and after short-term treatment
of progesterone and allopregnanolone (Smith et al., 1998; Concas
et al., 1999; Follesa et al., 2001; Gulinello et al., 2001). The α6 sub-
unit is highly sensitive to pentobarbital (Thompson et al., 1996)
and neurosteroids (Belelli et al., 2002).
The γ2 subunit is also involved in anxiety regulation, and it
is changed during hormone treatment and pregnancy (Essrich
et al., 1998; Follesa et al., 1998; Concas et al., 1999; Crestani
et al., 1999; Kittler et al., 2000). The δ-subunit is responsible
for tonic conductance and important for neurosteroid modula-
tion on GABAA-receptor (Stell et al., 2003). Interestingly, receptor
knockout studies have revealed that the absence of the δ-subunit
decreases the sensitivity to neurosteroids such as pregnanolone
and alphaxalone, thereby inﬂuencing the duration of anesthesia
and the anxiolytic effect of those steroids (Mihalek et al., 1999).
Finally, the ε-subunit reduces neurosteroid and anesthetic mod-
ulation (Davies et al., 1997; Belelli et al., 2002; Thompson et al.,
2002).
Functionally, distinct subunit-speciﬁc properties have been
identiﬁed in both recombinant and native receptors, supporting
the concept that GABAA-receptor heterogeneity is a major facet
determining the functional properties of GABAergic inhibitory
circuits (Sieghart, 2000;Mohler et al., 2001). In particular, the type
of α-subunit determines the kinetics of receptor deactivation (Ver-
doorn et al., 1990; Hutcheon et al., 2000; Devor et al., 2001), and
the presence of the δ-subunit results in markedly increased agonist
afﬁnity and apparent lack of desensitization (Burgard et al., 1996;
Fisher and Macdonald, 1997; Adkins et al., 2001).
The GABAA-receptor expresses different subunit compositions
in different parts of the brain (Sieghart and Sperk, 2002). The
subunit composition is related to different function of the spe-
ciﬁc part of the brain (Korpi et al., 2007; Table 2). This anatomical
diversity constitutes the very basis for the pathogenesis of different
conditions. Steroids interact differently with the GABAA-receptor
depending on the subunit composition (Belelli et al., 2002). The
α5 subunit is localized in high degree in the hippocampus, a key
area for memory and learning, α5 is shown to be important for
learning and memory function (Table 2) since α5-subunit knock-
out mice in comparison with wild-type mice show signiﬁcantly
better performance in a water maze model of spatial learning
(Collinson et al., 2002). In addition, blockade of the GABAA-
receptor subunit α5 increased learning and memory (Casula et al.,
2001;Maubach,2003).GABAA-receptor activation can inhibit LTP
induction and NMDA receptors, which are involved in the regu-
lation of hippocampal-dependent spatial memory (Riedel et al.,
2003).
Several papers report changes in the GABAA-receptor sub-
unit composition and decreased GABA function after long-term
exposure to GABAA-receptor agonists (Miller et al., 1988; Belelli
et al., 2002). It is well-known that tolerance develops during long-
term GABAA-receptor exposure. Tolerance development is noted
already after 90min exposure to anesthetic dosages of allopreg-
nanolone. Changes in the α4 subunit of the GABAA-receptor in
thalamus were related to the tolerance development (Birzniece
et al., 2006a). GABA-steroids are positive neurosteroid modula-
tors on the GABAA-receptor (Majewska et al., 1986). Long-term
treatmentwithGABA-steroidsmay induce down-regulation of the
GABAA-receptor function in mammalian cultured neurons both
for neuroactive steroids and other GABAA-receptor active drugs
(Yu and Ticku, 1995a; Yu et al., 1996). During pregnancy when
allopregnanolone is high there is a decrease in GABAA-receptor
function and changes in subunit composition of the GABAA-
receptor. Inhibiting the synthesis of allopregnanolone blocked
these changes (Concas et al., 1998). Chronically high cortisol levels
Table 2 | Relationship between behavior disorders/symptoms, brain areas, and subunits of the GABAA-receptor.
Behavior disorders/symptoms Brain region GABAA-receptor subunit
Memory and learning disruption Hippocampus α5 δ
Anxiety and mood disturbance Hippocampus; amygdale α2 α4 β3 δ
Fatigue, sedation, and exhaustion Wide spread α1
Depression induced by stress α1 α3 β1 β2 δ γ2
Eating disorders Hypothalamus α3
Relapse in alcohol abuse β6
Balance and mobility disorders Cerebellum α6 β2 δ
Epilepsy and excitability disorders α1 β3
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and GABA-steroids give irreversible cognitive damages. A reduced
sensitivity to benzodiazepines, alcohol, and GABA-steroid is also
seen in women with PMDD during the luteal phase. Such a change
in GABAA-receptor sensitivity, as measured by reduced sedation
and saccadic eye velocity response to GABA active compounds,
contributes to symptom severity of PMDD patients (Backstrom
et al., 2003). In a rat model of PMDD, allopregnanolone upreg-
ulates the α4 subunit of the GABAA-receptor in hippocampus
parallel to the induction of anxiety (Smith et al., 1998; Gulinello
et al., 2001). In addition, the anxiety induction was blocked if
the animals were treated with α4-antisense (Smith et al., 1998;
Gulinello et al., 2001). With a further developed rat model of
PMDD, the authors addressed that the high risk-taking rats are
those react with anxiety in the PMDDmodel (Lofgren et al., 2006).
SYNAPTIC AND EXTRASYNAPTIC GABAA-RECEPTORS
The GABAA-receptors can either be synaptic (located within
the synaptic cleft) or extrasynaptic (located outside the synaptic
cleft; Fortin et al., 2004). The synaptic receptors usually contain
γ-subunits and can be rapidly expressed at the neuronal mem-
brane and are sensitive to both benzodiazepines andneurosteroids.
Extrasynaptic GABAA-receptors are in a preferred position to be
activated by the low levels of ambient GABA, due to their high
GABA afﬁnity in contrast to the lower afﬁnity of synaptic GABAA -
receptors (Saxena and Macdonald, 1994;Mody, 2001; Brown et al.,
2002; Farrant and Nusser, 2005). The high-afﬁnity extrasynaptic
GABAA-receptors consist of speciﬁc subunit combinations dif-
ferentially expressed in various brain regions. These include the
δ-subunit containing GABAA-receptors of dentate gyrus and cere-
bellar granule cells, cortical and thala mic neurons (Nusser et al.,
1998; Sur et al., 1999; Pirker et al., 2000; Nusser and Mody, 2002;
Stell et al., 2003; Sun et al., 2004; Cope et al., 2005; Jia et al.,
2005; Drasbek and Jensen, 2006), and the α5-subunit containing
GABAA-receptors in CA1 and CA3 pyramidal cells (Sperk et al.,
1997; Caraiscos et al., 2004; Glykys and Mody, 2006). The cur-
rent mediated by these extrasynaptic receptors has been termed
tonic inhibition (Brickley et al., 1996; Farrant and Nusser, 2005),
which is highly sensitive to the extracellular GABA concentra-
tion (GABA). It is enhanced when ambient (GABA) is increased
by blocking GABA transporters, by adding GABA to the aCSF
to mimic that normally present in the extracellular space, or by
preventing GABA degradation (Nusser and Mody, 2002; Stell and
Mody, 2002; Wu et al., 2003; Glykys and Mody, 2006).
The δ-subunit is highly sensitive to GABA and neurosteroids
but not to benzodiazepines (Brown et al., 2002; Smith et al., 2007).
It also appears that speciﬁc types of receptor subunit combina-
tions are expressed in the synaptic cleft and extra synaptically. For
example, the α1β2/3γ2, α2β2/3γ2, and α3β2/3γ2 receptors are the
predominant synaptic receptors (Farrant and Nusser, 2005) and
the combinations of α6βnδ, α4βnδ, α1βnδ, and α5βnγ2 receptors,
are predominantly or exclusively extrasynaptic (Nusser et al., 1998;
Fritschy andBrunig,2003;Glykys andMody,2007). In the synapse,
each vesicle is thought to release several thousands of GABA mol-
ecules into the synaptic cleft which leads to a high concentration
of GABA (0.3–1.0mM) in a time span of 10–100ms (Mozrzymas
et al., 2003; Semyanov et al., 2004). Furthermore, it is suggested
that there are rather few receptors, from 10 to a few hundreds,
located opposite to the release site (Mody et al., 1994; Nusser et al.,
1997; Brickley et al., 1999).
Synaptically releasedGABAwhich act on postsynaptic GABAA-
receptors is termed “phasic” inhibition, whereas the term “tonic”
inhibition refers to a continuous activation of extrasynaptic recep-
tors by ambient GABA (Farrant and Nusser, 2005). The main
feature of phasic inhibition is the rapid synchronous opening of a
relatively small number of channels that are clustered within the
synaptic cleft. This enables a resolution both in time (the release
is triggered by an incoming action potential) as well as in space
(the release is limited and thereby the postsynaptic action, to a
speciﬁc synapse. In contrast, tonic inhibition results from ambi-
ent GABA and therefore is relatively constant in both time and
space. Although both modes of action clearly impact upon neu-
ronal information processing at the cellular and network level, the
extent to which each type of inhibition inﬂuences brain excitabil-
ity in normal and diseased states is not known. GABA-mediated
tonic conductance is found in granule cells of the dentate gyrus
(Nusser and Mody, 2002; Farrant and Nusser, 2005), thalamocor-
tical relay neurons of the ventral basal complex (Porcello et al.,
2003), layer V pyramidal neurons in the somatosensory cortex
(Yamada et al., 2004), CA1 pyramidal cells (Bai et al., 2001), and
certain inhibitory interneurons in the CA1 region of the hip-
pocampus (Semyanov et al., 2003). Unlike receptors mediating
phasic current, tonically active GABAA-receptors show unusual
high GABA afﬁnity (Saxena and Macdonald, 1996) and be acti-
vated by the low ambient GABA concentrations (nanomolar to
few micromolar; Lerma et al., 1986; Tossman et al., 1986). At
sub-micromolar concentrations, several competitive, and non-
competitive GABAA-receptor antagonists (gabazine, picrotoxin,
and bicuculline) reduced phasic currents, but had no effect on
tonic currents. However, the antagonists blocked both phasic and
tonic currents at high concentrations (Bai et al., 2001; Stell and
Mody, 2002; Semyanov et al., 2003; Yeung et al., 2003; Farrant and
Nusser, 2005).
THE EFFECT OF NEUROSTEROIDS ON THE GABAA-RECEPTOR
The GABAA-receptor can be modulated by a number of therapeu-
tic agents, including benzodiazepines (Sieghart, 1992; Macdonald
and Olsen, 1994), barbiturates (Smith and Riskin, 1991), anes-
thetics, ethanol (Harris et al., 1995), zinc (Smart, 1992), and
neurosteroids (Puia et al., 1990; Hawkinson et al., 1994a; Lam-
bert et al., 2001b). The effect of neurosteroids on the GABAA-
receptor depends on the type of steroids (agonist or antagonist),
the type of receptors (synaptic of extrasynaptic), the subunit
compositions, and the intrinsic structure of the steroid. Recent
studies indicate that the existence of at least two neurosteroid
actions on the GABAA-receptor, namely an agonistic action and
an antagonistic action by the sulfated and 3β-OH steroids. The
agonistic action can further be divided into an allosteric enhance-
ment of GABA-evoked Cl− current and a direct activation of the
GABAA-receptor.
The synaptic currents originates from a short exposure of
high concentrations of GABA that induces receptor desensitiza-
tion (Jones and Westbrook, 1995). As a consequence of this, the
mechanism of neurosteroid modulation at the GABAA-receptor
cannot easily be predicted by studies of currents evoked by low
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concentrations of GABA. It has been shown that allopregnanolone
remarkably increases the decay time of sIPSC (Haage and Johans-
son, 1999; Belelli and Lambert, 2005), which likely depends on a
reduced GABA unbinding rate from the receptor. However, a dif-
ferent mechanism was suggested for the 3α5α-THDOC induced
decay time prolongation. Here it was instead suggested that the
underlying mechanism was altered kinetics of desensitized states
(Zhu and Vicini, 1997). The above explanations for the mecha-
nisms underlying the effects of neurosteroids is based on the idea
that once GABA is bound to the receptor it can enter different
states of which some are open and some are closed (desensitized)
which will determine the shape of the evoked current (Jones and
Westbrook, 1995).
At low-micromolar concentrations of GABA,allopregnanolone
instead increases the activation rate and induces amore prominent
desensitization of GABA-evoked currents (Haage and Johans-
son, 1999). Interestingly, there is also evidence that the effect
of 3α5α-THDOC to prolong the deactivation time (which is the
same as the decay time but is used for externally applied GABA)
depends on the age. The effect on the deactivation of GABA
response in cerebellar neurons is greater in younger rats than
adult rats (Zhu and Vicini, 1997). In summary, we believe that
the prolongation of deactivation and altered receptor kinetics
in terms of entry and exit from desensitized states, are essential
to the allosteric modulation of the GABAA-receptor by neuros-
teroids. Agonistic neurosteroids affect not only the time course
of sIPSC but also the frequency of the sIPSCs. Such an increase
in frequency is due to the presynaptic effect of neurosteroids
(Poisbeau et al., 1997; Haage et al., 2002) by a mechanism that
involves altered presynaptic Ca2+ permeability and activation of
presynaptic GABAA-receptors.
The effect of neurosteroids on the GABAA-receptor can be
attributable to variations in the receptor subunit composition.
The action of allopregnanolone was not inﬂuenced by the α-
subunit, when co-expressed with β1- and γ2-subunit in Xenopus
oocytes (Belelli et al., 2006). The GABA responses at α1β1γ2 and
α3β1γ2 receptor are enhanced by low concentration of allopreg-
nanolone (≥3 nM), whereas several folds higher concentrations
are needed to obtain the equivalent response on α2-,α4-, α5-,
or α6-subunit containing receptors. Likewise, the subtypes of
the β-subunit (β1–3) have little action on the effects of neu-
rosteroids (Hadingham et al., 1993; Sanna et al., 1997; Belelli
et al., 2002). The presence of a γ-subunit is not a prerequisite
for the neurosteroid activity. In fact, the efﬁcacy of allopreg-
nanolone action at the binary α1β1 receptor is higher than that
at the ternary α1β1γ2 receptors (Maitra and Reynolds, 1999;
Belelli et al., 2002). Given the γ-subunit have little or no effect
on the maximal GABA-modulation effect of allopregnanolone, it
signiﬁcantly inﬂuences the potency of the steroid with “physio-
logical concentrations” (3–30 nM; Belelli et al., 2002). However,
the inhibition of GABAA-receptor by PS did not vary between
binary and ternary receptor (Wang et al., 2006). The poten-
cies and efﬁcacies of PS to inhibit GABA saturating concen-
tration at the α1β2γ2L and α1β2 receptor were identical (Wang
et al., 2006). On the other hand, δ-subunit when co-expressed
with α4- and β3-subunits, a receptor thought to be naturally
present in the thalamus (Sur et al., 1999) shows high steroid
sensitivity compare toγ-subunit containing receptor (Davies et al.,
1997; Belelli et al., 2002). Receptors incorporating the ε-subunit
are reported to be insensitive to the modulation by pregnane
steroids, not the direct GABA-mimetic effect (Lambert et al.,
2001b).
SYNAPTIC EFFECT OF NEUROSTEROIDS
The brief inhibitory response of neurosteroids by activating
the postsynaptic GABAA-receptor is a phasic response. Synaptic
GABAA-receptors are ternary complexes that commonly incorpo-
rate the γ2 subunit in combination with one α (mainly α1/2/3) and
one β2/3 subunit. However, these receptor isoforms can also be
located extrasynaptically (Farrant and Nusser, 2005). The kinetic
of agonist steroids at synaptic GABAA-receptor has been stud-
ied thoroughly by measuring the sIPSC from neurons in brain
slice. Neurosteroids have little effect on the onset time and peak
amplitude of the sIPSC. Agonist neurosteroids prolong the decay
time constant of IPSC (Majewska et al., 1986; Zhu and Vicini,
1997; Haage et al., 2005). However, this effect is neuron speciﬁc. In
hippocampal CA1 neurons, cerebellar granule cells and Purkinje
neurons, neurosteroids prolong the sIPSC at relatively low concen-
tration (in the nanomolar range; Cooper et al., 1999; Vicini et al.,
2002;Harney et al., 2003).On the other hand,micromolar concen-
trations are required to produce equivalent responses in oxytocin
neurons of hypothalamus (Brussaard et al., 1997; Koksma et al.,
2003).Moreover, in the preoptic cells in the hypothalamus,100 nM
allopregnanolone prolong the spontaneous current (Haage et al.,
2005; Stromberg et al., 2006). This indicates that the neurons in
the same brain region can show heterogeneity. In addition, the
effect of 3α5α-THDOC on GABA-binding kinetic is more pro-
found in the hippocampal CA3 and subiculum than that in CA1
and entorhinal cortex (Nguyen et al., 1995). At higher concen-
trations (>10μM) which can occur in the brain during partu-
rition (Stoffel-Wagner, 2003), neurosteroids activate the GABAA-
receptor directly (Majewska et al., 1986) in a similar pattern as
barbiturates by interactingwith different sites onGABAA-receptor
(Kerr and Ong, 1992). This “GABA-mimetic” effect of neuros-
teroid is sufﬁcient to suppress the excitatory neurotransmission
(Shu et al., 2004).
EXTRASYNAPTIC EFFECT OF NEUROSTEROIDS
The response of neurosteroids at relatively low concentrations
is mediated by the activation of extrasynaptic GABAA-receptors
containing α4, α6, and δ-subunits. Extrasynaptic receptors iden-
tiﬁed at the granule cells of the dentate gyrus and cerebellum,
and the relay neurons of the thalamus, are distinct from the
synaptic receptors. Extrasynaptic conductance can have a con-
siderable inﬂuence on neuronal excitability (Leroy et al., 2004).
Extrasynaptic receptors exhibit both a high GABA afﬁnity and
reduced receptor desensitization in the continued presence of
the agonist (Fritschy and Brunig, 2003). Such properties ren-
der these receptors ideally suited to sense the low ambient con-
centrations (∼0.5–1μM) of the extrasynaptic neurotransmitters
(Kennedy et al., 2002). Extrasynaptic receptors containing the
δ-subunit are highly sensitive to neurosteroids in certain brain
region (Wohlfarth et al., 2002). At low “physiological” concentra-
tions (10–100 nM), 3α5α-THDOC selectively enhance the tonic
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conductance, with little or no effect on the phasic conductance
in mouse DGCs and CGCs (Stell et al., 2003; Belelli and Lam-
bert, 2005; Farrant and Nusser, 2005). Tonic inhibition is reduced
in the δ-subunit “knockout” mice, and the residual tonic cur-
rent was insensitive to 3α5α-THDOC (Mihalek et al., 1999; Stell
et al., 2003). However, the extrasynaptic effects of neurosteroids
also reveal regional difference in the CNS. Two hundred ﬁfty
nanomolar 3α5α-THDOC has no effect on the tonic inhibition
in ventrobasalis complex of the thalamus (Porcello et al., 2003).
On the other hand, the tonic conductance of hippocampal CA1
neurons expressing GABAA-receptor with α5 subunit is affected
by 3α5α-THDOC (≥100 nM; Stell et al., 2003; Belelli and Lam-
bert, 2005; Farrant and Nusser, 2005). It is suggested that the
modulation of tonic currents is inﬂuenced by local neurosteroid
metabolism. The inhibition of metabolism can greatly enhance
the response of the tonic current in dentate granule cells to
endogenous neurosteroids, but not on the synthetic metaboli-
cally stable ganaxalone (Belelli and Herd, 2003). Neurosteroid
metabolism reveals regional speciﬁcity that also contributes to
the regional speciﬁcity of the tonic GABAA-receptor mediated
currents. In summary, evidence is emerging that the GABAA-
receptor mediated tonic conductance present in some neurons
may have a considerable inﬂuence on neuronal signaling and
network activity (Brickley et al., 2001; Hamann et al., 2002;
Mitchell and Silver, 2003). The high sensitivity of neurosteroids
in extrasynaptic receptor may represent an important target for
neurosteroids.
AGONIST NEUROSTEROIDS ON THE GABAA-RECEPTOR
The structure–activity relationship of neurosteroid actions on the
GABAA-receptor has been summarized in a number of articles
(Laubach et al., 1955; Gyermek et al., 1968; Gyermek and Soyka,
1975; Sear, 1997). The systemic investigation of several isomers
of GABAA-receptor active neurosteroids revealed a couple crucial
structure variations (Figure 2), namely the geometry between ring
A/B; a hydrogen-bond donator in C3 position; a hydrogen-bond
acceptor in C20 position and/or a ﬂexible bond at C17 position
(Purdy et al., 1990; Zorumski et al., 2000; Ragagnin et al., 2007).
The α- and β-conﬁguration refer to constituents below and above
the plane of the steroid backbone. Variation of the core and sub-
stitution in certain positions of the steroid molecules has crucial
consequence on the neurosteroid effects (Figure 2).
Anesthetic steroids typically have a saturated backbone of four
rings, although this is not an absolute requirement for activity.
The four rings form a rigid framework for positioning the hydro-
gen bonding groups in three-dimensional spaces (Figure 2). The
presence of hydrogen-bond donor in the α-conﬁguration at C3
and β-conﬁguration at C17 are critical for the sedative action of
agonist neurosteroids (Purdy et al., 1990; Hawkinson et al., 1994b;
Hogenkamp et al., 1997). These groups are important for the bind-
ing of neurosteroids to a variety of proteins by means of hydrogen-
binding with polar or charged residues (Brzozowski et al., 1997;
Grishkovskaya et al., 2000). Replacing the hydrogen of hydroxyl
with methyl, thus eliminating the ability of the steroid to donate a
hydrogen bond in this region, results in dramatic reduction in
its potency (Upasani et al., 1997). Replacing the steroid skele-
ton with an alicyclic framework like 2-cyclohexylideneperhydro-4,
FIGURE 2 | Features of general structure of the neurosteroid. Figure
shows intact four ring system that often contains hydroxyl side chains as
sterols. Hydroxyl groups are denoted α if they are oriented above the plane
(solid line), and α if they are oriented below the plane (dashed line).
Stereoisomerism and structural modiﬁcations were discussed at carbon 3,
5, 6, 7, 17, 20, and 21 positions.
7-methanoindene derivatives give a compound that showed weak
potentiating activity (Burden et al., 2000). When the carbonitrile
is replaced with an acetyl group the derivatives become inactive
(Hamilton, 2002).
The conﬁguration of C5-reduction is important to potency.
Even if steroids with either 5α or 5β conformations are active, spa-
tial difference in this position may affect the pharmacology of the
neurosteroids. Allopregnanolone with 5α-reduction is generally
morepotent than its 5β-isomer,pregnanolone,asGABAA-receptor
agonist both in vivo and in vitro. Studies with 3α5α-THDOC and
its stereoisomer 3α5β-THDOC revealed important differences in
potency, efﬁcacy, and regional selectivity at theGABAA-receptor in
favor of 5α-reduction (Gee and Lan, 1991; Mennerick et al., 2004).
5α-steroid, but not 5β-steroids, showed a high degree of enantios-
electivity/enantiospeciﬁcity in their action as modulator of the
GABAA-receptor and as anesthetics (Covey et al., 2000). The efﬁ-
cacy of 3β5β-P to inhibit GABAA-receptor is signiﬁcantly different
from 3β5α-P (Rahman et al., 2006; Wang et al., 2007). 5β-reduced
antagonist neurosteroids cause signiﬁcant higher inhibition than
the 5α-isomers.
Like pregnan steroids, metabolites of testosterone such as
androstanediol are also modulators of GABA. It was found that
the systemic 3α-androstanediol administration conditions a place
preference more effectively than does systemic administration
of dihydrotestosterone or testosterone (Frye, 2001). Additionally,
plasma concentration of 3α-androstanediol is increased compare
to dihydrotestosterone and testosterone. However, the potency
and efﬁcacy effect of 3α-androstane steroid is lower than those
of 3α-pregnan steroids (Rahman et al., 2006).
ANTAGONIST NEUROSTEROIDS ON THE GABAA-RECEPTOR
Neurosteroids may both enhance and inhibit GABAergic neuro-
transmission (Wang et al., 2002; Mennerick et al., 2004; Rahman
et al., 2006; Stromberg et al., 2006). It has been shown earlier that
3β-hydroxy A-ring reduced pregnane steroids (3β-OH steroids)
and pregnenolone sulfate inhibit GABAA-receptor coupled anion
channels (Wang et al., 2002, 2007; Lundgren et al., 2003; Birzniece
et al., 2006b). 3β-OH steroids and PS, at concentrations that had
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little effect on GABAergic synaptic currents, signiﬁcantly reversed
the potentiating effect of 3α-OH A-ring reduced steroids (Wang
et al., 2002). Although antagonistic steroids reduced the potentia-
tion induced by 3α-OH steroids, they still acted non-competitively
with respect to the agonistic steroids and inhibited a larger poten-
tiation more efﬁciently (Wang et al., 2002). Furthermore, 3β-OH
steroids co-appliedwithGABA alone signiﬁcantly inhibitedGABA
responses at concentrations≥EC50 (Garrett andGan,1998;Maitra
and Reynolds, 1998;Wang et al., 2002; Lundgren et al., 2003). This
direct, non-competitive effect of 3β-OH steroids and PS on the
GABA response was sufﬁcient to account for the apparent antago-
nism of agonist steroids (Rahman et al., 2006). In summary, both
PS and 3β-OH steroids inhibited the GABAA-receptor more effec-
tively under conditions that promoted agonist binding or channel
opening (Wang et al., 2002). The interaction between antagonist
and agonist steroids was due to a use-dependent action of antago-
nist steroids at recombinant and synapticGABAA-receptors (Wang
et al., 2002).
MECHANISM OF PREGNENOLONE SULFATE AND NEUROSTEROID
SULFATE ESTERS
Sulfated steroids like pregnenolone sulfate and dehydroepiandros-
terone sulfate can produce profound effects on behavior. PS as
an abundant neurosteroid enhances learning (Mayo et al., 1993;
Flood et al., 1995), and antagonizes the impairment of learning
andmemory produced by ethanol and scopolamine (Melchior and
Ritzmann, 1996). PS may play a role in cognition and have been
reported as negative modulators of the GABAA-receptor based on
electrophysiological studies and GABA-mediated 36Cl− uptake by
rat brain synaptosomes (Majewska et al., 1990; Demirgoren et al.,
1991). Structure–activity relationships of GABAA-receptormodu-
lation are different for sulfated inhibitory steroids vs. non-sulfated
potentiating steroids (Park-Chung et al., 1999). Potentiation by
non-sulfated steroids requires 3α-stereochemistry. Pregnenolone
by itself is inactive on the GABAA-receptor. In contrast, both 3α-
and 3β-isomers of PS is inhibitory. Although the addition of a
negatively charged sulfate group or hemisuccinate group at the
C3 position converts the neurosteroid from being potentiating to
inhibitory (Park-Chung et al., 1999), a negatively charged group
at C3 is not absolutely essential for inhibition since the non-
sulfated neurosteroid DHEA is also inhibitory. However, DHEA
is less potent than its sulfated derivative DHEAS (Imamura and
Prasad, 1998; Park-Chung et al., 1999). Steroids such as 11-keto
derivative of PS are of particular interest, as it behaves as a posi-
tive, negative, or neutral modulator on the GABAA-receptor. It is
suggested that 11-keto pregnenolone sulfate (11-keto PS) exerts
a dual action on distinct positive and negative steroid modula-
tion sites associated with the GABAA-receptor (Park-Chung et al.,
1999).
Consistent with the idea that PS induces activation-dependent
inhibition on the GABAA-receptor (Wang et al., 2002), another
report revealed that the inhibition of basal inhibitory postsynap-
tic currents (IPSCs) by antagonist steroids was correlated with
the basal decay time of the IPSCs (Eisenman et al., 2003). Analy-
sis of single-channel behavior in the presence of GABA and PS
suggested no difference in the ability of PS to block liganded
closed vs. liganded open receptors (Akk et al., 2001). These results
leave open the possibility that PS may prefer liganded over unli-
ganded receptors, consistent with a model of state-dependence to
PS actions.
An earlier study observed that PS inhibits GABA-gatedCl− cur-
rent by enhancing receptor desensitization and stabilizing desen-
sitized state with prolonged application of low-afﬁnity GABA
agonists to nucleated membrane patched (Shen et al., 2000). Note
that the promotion of desensitization is selective for prolonged
GABA applications (Shen et al., 2000). It is well-known that the
time course of GABA-mediated IPSCs is inﬂuenced strongly by
the kinetics of the GABAA-receptor desensitization (Celentano
and Wong, 1994; Jones and Westbrook, 1995). Desensitized states
are thought to buffer receptors in bound conformations that
make it possible for channels to re-open before GABA unbinds.
The fast phase of desensitization limits the open probability of
the channels, inﬂuences peak synaptic currents, and contributes
to the fast component of IPSC decay. The slow component of
decay may result from reopening of GABA channels after exit
from desensitized states (Jones and Westbrook, 1995). On the
other hand, recombinant GABAA-receptors composed of deﬁned
subunit combinations also give rise to currents with complex
decay kinetics (Lavoie et al., 1997; Haas and Macdonald, 1999).
In cultured hippocampal neurons, PS decreases the peak current
of the inhibitory autapic currents, enhances the fast and slow
phases of deactivation after brief application of a few millisec-
onds. After longer application (∼100ms or more), PS enhances
both the fast and slow phases of desensitization of the GABA
current (Shen et al., 2000; Eisenman et al., 2003). Moreover,
PS reduces the agonist steroid evoked prolongation of sIPSC
and reduces channel-opening frequency (Mienville and Vicini,
1989). However, recording the sIPSC of neurons medial preoptic
nucleus (MPN) shows that PS neither affects the peak ampli-
tude nor the decay of sIPSC (Haage et al., 2005). Instead, PS
reduces the frequency of the sIPSC at higher concentration (Haage
et al., 2005). The main effect of PS on the sIPSC time course is
explained by a simpliﬁed model that this substance reduce the rate
of desensitization while the agonist steroids assumed to reduce
the unbinding rate of GABA from the receptor (Haage et al.,
2005).
MECHANISM OF 3β-HYDROXYSTEROID AS GABAA-RECEPTOR
ANTAGONIST
According to earlier studies, PS (Woodward et al., 1992), 3β-
OH steroids, or carboxylated steroids (Mennerick et al., 2001)
are more effective against GABA responses gated by high con-
centrations of GABA. In electrophysiological studies, 3β5β-P
antagonized the 3α5β-P induced enhancement of GABA cur-
rent (Maione et al., 1992; Maitra and Reynolds, 1998). On the
other hand, 3β5α-P diminished the inhibitory effects of 3α5α-
P on population spikes evoked in rat hippocampal CA1 stratum
pyramidal (Wang et al., 2000). Studies on the chloride uptake
into synaptosomes in rat cerebral cortex, in hippocampus and
sIPSC in MPN showed that 3β-OH steroids reduced the 3α5α-P
enhanced GABA response (Stromberg et al., 2006). In the pres-
ence of low concentration GABA, some of the 3β-OH steroids
potentiated GABA-evoked chloride ion uptake and prolonged
the decay time, whereas the others had little or no effect on
Frontiers in Endocrinology | Neuroendocrine Science October 2011 | Volume 2 | Article 44 | 8
Wang Neurosteroids and GABAA-receptor function
GABA stimulated current. Therefore, certain 3β-OH steroids,
namely 5β-pregnane-3β, 20(S)-diol and 3β-OH-5β-pregnane-20-
onehave both agonistic and antagonist property (Wang et al., 2002;
Stromberg et al., 2006). Moreover, another study with the Cl−
uptake method has shown that 3β-OH-5α-pregnan-20-one is a
useful antagonist of 3α5α-P enhanced GABA response (Lundgren
et al., 2003). However, in GABAA-receptor expressed in Xeno-
pus oocytes showed that 3β-steroids inhibit GABA response at
near-saturating concentrations (Rahman et al., 2006). It is still
unclear why the effect of 3β-OH steroids varies with different
methods. It is likely that the steroid structure, drug application
time and base line GABA concentration may be responsible for
the discrepancy.
It is suggested that a homologous mutation of the residue at
2′position closest to the cytoplasmic end of the M2 helix to serine
on both the β1 and the β2 subunit,α1V256S and β2A252S, reduced
the desensitization rate of GABA-activation at saturating doses
(Wang et al., 2007). In a receptor complex with reduced desensi-
tization components to GABA-activation (e.g., mutant receptors),
the PS-inhibition was also greatly reduced (Akk et al., 2001).
On the other hand, PS has been shown earlier to increase the
deactivation rate of the GABA-evoked sIPSCs recorded by patch-
clamp techniques at the acutely dissociated neurons from the
MPN area of the rat brain slice (Haage et al., 2005). Recent
studies conﬁrmed the ﬁndings that PS increased the fast offset
rate of GABA-activation (Wang et al., 2007). However, the slow
component of the offset time course was decreased by PS in a
dose-dependent manner. The potencies of 5α-pregnan-3β, 20α-
diol and 5β-pregnan-3β, 20β-diol to inﬂuence offset time courses
of GABA-activation were signiﬁcantly lower than PS, in accor-
dance with our earlier ﬁndings while PS was signiﬁcantly more
potent to inhibit both peak and steady-state GABA currents than
3β-OH steroids (Wang et al., 2002, 2006, 2007). PS-inhibition was
already seen at low dose of GABA response (≤EC20; Eisenman
et al., 2003), whereas the inhibition by 3β-OH steroids on the cur-
rent response was ﬁrst seen at higher end (>EC50) of the GABA
dose-response curve (Wang et al., 2002). Obviously, 5α-pregnan-
3β, 20α-diol and 5β-pregnan-3β, 20β-diol prolonged the fast offset
time course of GABA response, suggesting that the inherent associ-
ationbetween3β-OHsteroids and receptor has rather high afﬁnity.
However, it was not fully excluded that a more complicated model
of a multivalent interaction between hydrophobic steroids and
receptor is employed. Kinetic properties of 3β-OH steroids have
also been elucidated in acute dissociate neurons from the MPN
area of the hypothalamus (Stromberg et al., 2006). These steroids
have no effect on the activation phase or the maximum amplitude
of 3α5α-P enhanced IPSCs. They rather affect the slow deactiva-
tion phase. A recent report shows that 3β-OH steroids exert their
effect by reducing the 3α5α-P induced prolongation of decay time
constant (tdecay; Stromberg et al., 2006).
DIFFERENTIAL MODULATION OF ρ RECEPTOR CHANNELS BY
NEUROSTEROIDS
The ρ1 GABA receptor is constitutes a dominant inhibitory force
in the retina but is expressed at lower levels throughout the ner-
vous system. Drugs acting on the ρ1 receptor can be useful in
the treatment of a variety of visual, sleep, and cognitive disorders.
Selective antagonists of ρ receptors can prevent the development
of myopia and enhance learning and memory in rats in the Mor-
ris water maze task after intraperitoneal injection (Chebib et al.,
2009). Receptors containing the ρ subunit have been implicated in
apoptosis of hippocampal neurons (Yang et al., 2003) and regula-
tion of hormone release in the pituitary gland (Boue-Grabot et al.,
2000).
Several neurosteroids are shown to modulate the ρ1 recep-
tor channel. Allopregnanolone, 5α-THDOC, and 5α-pregnane-
3α-ol-11,20-dione (alphaxalone) potentiated the GABA-evoked
currents from ρ1 receptor channels and concomitantly
altered the deactivation kinetics by prolonging the decay
time. In contrast, pregnanolone, 5β-pregnane-3,20-dione (5β-
dihydroprogesterone), and 5β-THDOC inhibited the GABA-
elicited currents of the ρ1 receptor channel. In comparison to
GABAA-receptors, the modulation of ρ1 receptor channels by
neurosteroids occurred with relatively high concentrations and
was more prominent in the presence of low concentrations of
GABA. Structural comparison of these six neuroactive steroids
reveals that the key parameter in determining the mode of
modulation for the ρ1 receptor channel is the position of the
hydrogen atom bound to the ﬁfth carbon, imposing a trans-
or cis-conﬁguration in the backbone structure (Morris et al.,
1999).
A study focusing on the electrophysiological effects of
inhibitory steroids on the ρ1 receptor found that steroid inhibitors
could be divided into three major groups based on how mutations
to residues in the M2 transmembrane domain modiﬁed inhibition
(Li et al., 2007). A recent study from the same research group (Li
et al., 2010) selected representatives of the three groups (preg-
nanolone, tetrahydrodeoxycorticosterone, pregnanolone sulfate,
allopregnanolone sulfate and β-estradiol) to probe how these
steroids, as well as the non-steroidal inhibitor picrotoxinin, mod-
ify GABA-elicited ﬂuorescence changes from the Alexa 546 C5
maleimide ﬂuorophore attached to residues in the extracellular
region of the GABAA-receptor. The ﬂuorophore responds with
changes in quantum yield to changes in the environment, allow-
ing it to probe for structural changes taking place during channel
activation or modulation. The authors reported that the modula-
tors have speciﬁc effects on ﬂuorescence changes suggesting that
distinct conformational changes accompany inhibition (Li et al.,
2010). Results are consistent with the steroids acting as allosteric
inhibitors of the ρ1 GABA receptor and support the hypothe-
sis that divergent mechanisms underlie the action of inhibitory
steroids on the ρ1 GABA receptor.
THE SITE OF NEUROSTEROID AGONIST ON THE
GABAA-RECEPTOR
Neurosteroids bind to GABAA-receptors at a site that is distinct
from the recognition sites for GABA, benzodiazepines, and bar-
biturates. This results in allosteric modulation of GABA bind-
ing or channel gating. The ability of neurosteroids to potentiate
GABA-activated currents recorded from a variety of neurons indi-
cated that most isoforms of the GABAA-receptor should be capa-
ble of binding neurosteroid modulators (Mitchell et al., 2008).
This concept was supported by studies of recombinant GABAA-
receptors with differing subunit composition that revealed a wide
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spectrum of activity for neurosteroids at GABAA-receptors with
some minor variations in efﬁcacy (Puia et al., 1993; Lambert
et al., 1996; Maitra and Reynolds, 1999; Belelli et al., 2002). Neu-
rosteroid modulation lacking subunit selectivity suggested that
neurosteroids are binding to a site that is conserved throughout
most members of the GABAA-receptor family.
Studies using GABAA/glycine-receptor chimeras suggested an
allosteric action of neuroactive steroids at the N-terminal side
of the middle of the second transmembrane domain (M2) of
the GABAA-receptor β1 and/or α2 subunits (Rick et al., 1998).
Electrophysiological studies have conﬁrmed that neurosteroid
agonists enhance Cl−-currents by increasing both channel fre-
quency and channel open duration at GABAA-receptor (Callachan
et al., 1987; Puia et al., 1990; Zhu and Vicini, 1997). Neurosteroid
agonists do not require direct aqueous access to the receptor,
and membrane accumulation is required for receptor modula-
tion (Akk et al., 2005). Hosie et al. (2006) identiﬁed two dis-
crete binding sites in the receptor’s transmembrane domains that
mediate the potentiating and direct activation effects of neuros-
teroid agonists at the GABAA-receptor. The potentiating effect
of 3α5α-THDOC is mediated by a cavity formed by the α-
subunit transmembrane domains. On the other hand, the direct
activation of GABAA-receptor by 3α5α-THDOC is mediated by
interfacial residues between α and β-subunits, and is enhanced
by steroid binding to the potentiation site (Hosie et al., 2006).
These proﬁles indicate that two distinct neuroactive steroid bind-
ing sites may exist; αTHr236 and βTyr284 residues in the trans-
membrane domain initiate direct activation whereas αGln241
and αAsn407 mediate the potentiating response (Hosie et al.,
2006). The neurosteroid potentiation site was further identi-
ﬁed in the α1β2γ2S receptor by mutation of Q241 to methio-
nine or leucine, which reduced the potentiation of GABA cur-
rents by the naturally occurring neurosteroids, allopregnanolone,
or tetrahydrodeoxycorticosterone (THDOC; Hosie et al., 2006,
2007).
In order to address whether the potentiation site for neu-
rosteroids on GABAA-receptors is conserved amongst different
GABAA-receptor isoforms, Hosie et al. (2006) used chimera to
generate 100 models based on an alignment of the transmem-
brane domains of the GABAA-receptor α1 subunit and the nACh
receptor α chain and selecting the 10 best models, revealed that
the potentiation site is associated only with the a subunit and the
activation site is interfacial between the α- and β-subunit.
By using heterologous expression of GABAA-receptors in HEK
cells, in combination with whole-cell patch-clamp recording
methods, a relatively consistent potentiation by allopregnanolone
of GABA-activated currents was evident for receptors composed
of one a subunit isoform (α2–5) assembled with β3 and γ2S sub-
units (Hosie et al., 2009). By introducingmutantαβγ receptors, the
neurosteroid potentiation was dependent on the conserved gluta-
mine residue in M1 of the respective a subunit (Hosie et al., 2009).
Studying wild-type and mutant receptors composed of α4β3δ sub-
units revealed that the d subunit is unlikely to contribute to the
neurosteroid potentiation binding site and probably affects the
efﬁcacy of potentiation (Hosie et al., 2009).
In summary, the neurosteroid potentiation site was likely con-
tained entirely within or on the transmembrane domains of the
α-subunit. The importance of this site for neurosteroid binding
was also conﬁrmed by the functional data on mutant α1 subunit
that reduced the potentiation of GABA responses by many syn-
thetic steroids at α1β2γ2L receptors (Akk et al., 2008; Li et al.,
2009).
THE SITE OF NEUROSTEROID ANTAGONIST ON THE
GABAA-RECEPTOR
It is generally accepted that the sulfate moiety is critical in pro-
ducing a steroid that blocks rather than potentiates GABAA-
receptors (Park-Chung et al., 1999). The fact that an anionic
group is critical gave suggestion to us that the sulfate might actu-
ally interact with residues forming the binding site mediating
antagonism. However, no voltage dependency was observed with
pregnenolone sulfate-inhibition on the GABA response (Majew-
ska and Schwartz, 1987; Majewska et al., 1988; Akk et al., 2001),
which suggests that the charged sulfate moiety does not interact
signiﬁcantly with the membrane ﬁeld as PS approaches the transi-
tion state between unbound and unblocked to bound and blocked
(Woodhull, 1973). Therefore, the lack of voltage dependence of
pregnenolone sulfate-inhibition suggests that it is unlikely that
the sulfate moiety interacts with a site deep within the channel
(Akk et al., 2001). Results from our earlier report suggest that
pregnenolone sulfate was a γ2-subunit independent inhibitor at
GABAA-receptors (Wang et al., 2006). However, residues deep
in the channel at the 2′ position in the M2 helix of both α1-
and γ2-subunit were critical for pregnenolone sulfate-inhibition
(Akk et al., 2001; Wang et al., 2002, 2006). Theoretically, a large,
rigid molecule such as a steroid would bind end-on rather than
with its long axis across the channel. It is thus possible that
either the A-ring (where the sulfate moiety is attached) or the
D-ring (the other end of the molecule) would penetrate the Cl−
channel most deeply. The lack of voltage dependence indicates
that the A-ring is unlikely to penetrate to the 2′ position. The
structure of the D-ring of PS is identical to that for many 3β-
hydroxysteroids. Since the inhibitory properties of 5α-pregnan-
3β, 20α-diol and 5β-pregnan-3β, 20β-diol were also reduced
in the α1Mβ2γ2L receptor, we think it is more likely that the
uncharged portions of the steroid molecules interact with the 2′
residue closest to the cytoplasmic end of the M2 helix on the α1
subunit.
The site of action of sulfated neuroactive steroids on GABAA-
receptors remains unclear. Based upon the observation that PS
reduced the apparent afﬁnity of [35S]-TBPS, Sousa and Ticku
(1997) suggested that PS and DHEAS might bind at the picro-
toxin/cage convulsant site. However, a mutation to the transmem-
brane M2 channel domain eliminated picrotoxin sensitivity but
the inhibitory effects of PS and DHEAS persisted (Shen et al.,
1999; Gibbs et al., 2006). The absence of voltage sensitivity or
alteration of single-channel open time argues against a binding
site within the pore. Akk et al. (2001) identiﬁed a valine residue
in the channel domain of the α1 subunit that slowed the devel-
opment of PS-inhibition when mutated to serine, but concluded
that this residue is unlikely to be part of the binding site and
likely inﬂuences PS action indirectly (Akk et al., 2001). Using
homologous mutation of the residue at 2′ position closest to the
cytoplasmic end of the M2 helix to serine on both α1 and β2
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subunit, namely α1V256S and β2A252S, it was found that effect
of PS is greatly reduced in these two mutant (Akk et al., 2001;
Wang et al., 2006, 2007). This suggests that these two amino
acids are involved in the PS mediated inhibition. However, it is
unclear whether these speciﬁc mutations at the cytoplasmic end
of M2 helix exert their effect by altering the allosteric mecha-
nism or by directly altering a binding site. A recent study in C.
elegans identiﬁed multiple residues in transmembrane domain 1
(M1), as well as a residue near the extracellular end of the M2
helix, that are critical for low-micromolar inhibition of C. ele-
gans GABAA-receptors by PS (Wardell et al., 2006). This latter
residue is of particular interest, as it is a positively charged argi-
nine that could potentially coordinate with the negatively charged
sulfate of PS. The C. elegans receptor exhibits some pharmaco-
logical differences as compared to mammalian GABAA-receptors
(for example, pregnanolone is inhibitory). So, these results may
or may not be relevant to mammalian receptors; however, it is
notable that an arginine residue is also found in this region of
mammalian GABAA-receptor subunits (Gibbs et al., 2006;Wardell
et al., 2006).
Block of responses to high-efﬁcacy agonists by this sulfated
steroid is greater than block of responses to partial agonists at sat-
urating concentrations. This is called “activation dependant” or
“state dependant inhibition” (Wang et al., 2002; Eisenman et al.,
2003). Picrotoxin, another GABA channel blocker superﬁcially
similar to pregnenolone sulfate in its activation dependence but
the site of action of PS does not require a functional picrotoxin
site for inhibition of GABA responses (Shen et al., 1999). The
GABA receptor antagonist Zn2+ also acts in activation dependant
manner. However, the Zn2+ binding site is located in the interface
between the α- and β-subunit and Zn2+ activity is minimal in
ternary αβγ receptor (Hosie et al., 2003).
GABA-STEROIDS AND THE MOOD CHANGE
Mood disorders are common health problems affecting women,
especially during fertile ages. It is suggested that periods of hor-
monal variability, i.e., menarche (Angold et al., 1999), premen-
strual periods (Soares et al., 2001), postpartum (Kendell et al.,
1981; Chaudron et al., 2001), and perimenopause (Freeman et al.,
2004) increase the risk of mood disorders in certain women.
There are three obvious examples in interaction between mood,
steroids, and CNS, namely PMDD, side effects of oral contracep-
tives and negativemood symptoms encountered during sequential
progestagen addition to estrogen treatment in postmenopausal
women.
An obvious relation between sex steroids and mood changes
are cyclic symptoms related to the menstrual cycle. Estradiol
and progesterone display regular predictable changes during the
menstrual cycle. In parallel with the increase of progesterone, an
increase also occur in serum concentrations of allopregnanolone
and pregnanolone (Wang et al., 1996). Although allopregnanolone
is synthesized in the brain, the major source to its brain con-
centration is the corpus luteum of the ovary (Bixo et al., 1997;
Ottander et al., 2005). Allopregnanolone and progesterone are
produced in parallel at the luteal phase of menstrual cycle (Wang
et al., 1996; Genazzani et al., 1998). In fertile women plasma
levels of allopregnanolone are approximately 0.2–0.5 nmol/L in
the follicular phase and up to 4 nmol/L in the luteal phase.
In the third trimester of a pregnancy, serum concentrations of
allopregnanolone can increase to more than 100 nmol/L (Bicikova
et al., 1995; Luisi et al., 2000). Pregnanolone displays a similar pat-
ternwith increase in the luteal phase (Wang et al., 1996; Sundstrom
et al., 1998).
GABA-steroids are positive modulators of GABA responses
on the GABAA-receptor (Majewska et al., 1986). Chemically
they are 3α-hydroxy-5α/β metabolites of progesterone (preg-
nanolone and allopregnanolone), testosterone (3α 5α-androstan-
diol), and desoxycorticosterone (tetrahydro-desoxycorticosterone,
THDOC). GABA-steroids enhance the GABA effect on chloride
ﬂux resulting in increased inhibition of neural activity (Majewska
et al., 1986; Gee et al., 1987; Birzniece et al., 2006b). GABA-
steroids induce sedation and can be used as anesthetic drugs
in human (Carl et al., 1990; Timby et al., 2006). GABA-steroids
are anti-epileptic (Backstrom et al., 1984; Landgren et al., 1987)
and in animal experiments they also possess an anxiolytic effect
similar to benzodiazepines (Wieland et al., 1991). An anxiolytic
effect of allopregnanolone has, however, never been shown in
humans.
Human and animal studies revealed typical GABAA-receptor
agonistic effects of allopregnanolone and pregnanolone at high
doses, i.e., sedation/anesthesia (Carl et al., 1990; Timby et al.,
2006), anti-epileptic effects (Landgren et al., 1998), and anxiolytic
effects in animals (Wieland et al., 1991). However, earlier reports
from human and animal models also indicated that all GABAA-
receptor agonists could induce negative symptoms with anxiety,
irritability/aggressiveness in certain individuals. Strong irritabil-
ity/aggression was induced in 3–6% of individuals and moderate
symptoms are induced in 20–30% (Masia et al., 2000; Weinbroum
et al., 2001). Interestingly, the prevalence of PMDDamongwomen
in reproductive age was in the similar range of 3–8%. The corre-
sponding prevalence of PMS, with milder symptom severity than
PMDD, was 25–35% of women in reproductive age (Sveindottir
and Backstrom, 2000).
It is puzzling why an increase in allopregnanolone during
the menstrual cycle is related to development of negative mood
as allopregnanolone should be anxiolytic agent like benzodi-
azepines. The answer depends on the fact that all GABAA-
receptor agonists such as benzodiazepines, barbiturates, alco-
hol, and allopregnanolone have paradoxical anxiogenic effects
in certain individuals. At low concentrations or doses they
give severe adverse emotional reactions in a subset of indi-
viduals (3–6%) and moderate reactions in up to 20–30% of
individuals. This paradoxical effect is induced by allopreg-
nanolone (Beauchamp et al., 2000; Miczek et al., 2003) ben-
zodiazepines (Ben-Porath and Taylor, 2002), barbiturates (Lee
et al., 1988; Kurthen et al., 1991; Weinbroum et al., 2001), and
ethanol (Cherek et al., 1992; Dougherty et al., 1996; Miczek
et al., 2003). Symptoms induced by these GABAA-receptor active
drugs are depressive mood, irritability, aggression, and other
symptoms known to occur during the luteal phase in women
with PMS/PMDD. A biphasic effect was also observed for
medroxyprogesterone (MPA) and natural progesterone in post-
menopausal women taking hormone therapy. These women felt
worse on a lower dosage of MPA or progesterone than on a
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higher dosage or placebo (Bjorn et al., 2002; Andreen et al., 2005,
2006).
Thus allopregnanolone seems to have a biphasic effect onmood
with an inverted U-shaped relationship between concentration
and effect. In postmenopausal women receiving progesterone, a
biphasic relation between the negative mood symptoms and the
plasma concentrations of allopregnanolone was observed. The
negative mood increased with the elevating serum concentration
of allopregnanolone up to the maximum concentration seen at the
luteal phase.With further increase in allopregnanolone concentra-
tion there was a decrease in symptom severity (Andreen et al.,
2005, 2006). An inverted U-shaped relation between allopreg-
nanolone dosage and irritability/aggression has also been noted
in rats (Miczek et al., 2003).
POSSIBLE EXPLANATIONS FOR THE PARADOXICAL EFFECT
OF GABA-STEROIDS
In this section, possible mechanisms of the biphasic response
curve of allopregnanolone onbehavioral parameters are discussed.
The basic idea of so called paradoxical effect where neuros-
teroids show one type of effect at low concentrations and another
type at high concentrations is that an enhanced GABAA-receptor
activity may give an excitatory net effect in certain situations,
instead of the usual inhibitory effect (Backstrom et al., 2011).
The following hypotheses suggest several possible mechanisms
how this can be achieved. In addition, there are no contradic-
tions between the different hypothesis and they may very well act
in parallel.
One explanation is based on that inhibitory neurons are the
most sensitive to GABA-steroids and therefore are the ﬁrst to be
inhibited at elevated steroid concentrations. This will give a release
of the inhibitory tone at excitatory neurons, a so called disin-
hibition. The idea emphasizes that speciﬁc combination of sub-
units determines the receptor sensitivity to neurosteroids (Belelli
et al., 2002; Stromberg et al., 2006). In this context, extrasy-
naptic GABAA-receptors containing the δ-subunit are of interest
because they seem to be more sensitive to GABA-steroids than
other types of subunit combinations (Mody, 2008). A possibil-
ity exists that one type of inhibitory neurons contains GABAA-
receptors with the δ-subunit, while the next in order contains
another subunit, making them less sensitive to GABA-steroids.
It has also been reported that the receptor subunit composition
and sensitivity to GABA-modulators can be regulated by environ-
mental factors such as stress (Biggio et al., 1990; Concas et al.,
1996).
Another idea is based on the ﬁnding that GABA-evoked cur-
rents at receptors with the α4β2δ combination are actually inhib-
ited, instead of potentiated, by allopregnanolone (Shen et al.,
2007). During stress allopregnanolone and other GABA-steroids
are produced and give an anxiolytic effect (Bitran et al., 1999).
However, Smith and colleagues showed that female mice reacted
with increased anxiety to stress during puberty (Shen et al., 2007).
In humans, puberty is often a period characterized by mood
swings and anxiety. This research group revealed that allopreg-
nanolone changed frombeing a positivemodulator of theGABAA-
receptor, at the time before and after puberty, to become a negative
modulator at the time of puberty (Shen et al., 2007). They also
reported that the change in effect coincide with an higher expres-
sion of the α4β2δ subunit combination (Shen et al., 2007). The
GABAA-receptor subunit combination that contains the δ-subunit
was known to be very sensitive to GABA-steroids, and is activated
by lower concentrations of allopregnanolone than other receptor
subtypes (Wohlfarth et al., 2002; Liang et al., 2004). Therefore,
the action of allopregnanolone at the α4β2δ receptor provides a
mechanism for the generation of negative mood at puberty. The
proposed hypothesis requires a higher number or proportion of
GABAA-receptors with the type(s) that are inhibited by steroids
also in other conditions when paradoxical steroid effects are seen
(PMDD/PMS). Actually, the α4βδ subunit composition was a key
factor in the progesterone withdrawal model for PMDD (Gallo
and Smith, 1993; Smith et al., 1998).
A third hypothesis is that the paradoxical effect arises when
the Cl− gradient across the membrane of critical neurons favors
an excitatory rather than inhibitory effect of GABAA-receptor
activation. The Cl− gradient across the cell membrane is subject to
active regulation andmay also vary between different types of neu-
rons as well as between different compartments within the neuron.
In adult vertebrate neurons, the intracellular Cl− concentration
was usually relatively low and, the GABAA-receptor activation
inhibited neuronal impulse activity. In contrast, during fetal and
early postnatal development, the intracellular Cl− concentration
was comparably high, and thus the GABAA-receptor activation
caused an excitation (Kahle et al., 2008). The intracellular Cl−
concentration is determined not only by passive ﬂux through the
GABAA-receptor and other Cl−-permeable channels, but also by
cation-Cl−-cotransporters, with the major inward transport often
mediated by NKCC1 and the major outward transport by KCC2
(Price et al., 2005, 2009; De Koninck, 2007). In adults, the out-
ward transport mediated by KCC2 dominates, which keeps the
intracellular Cl− concentration low.
However, the intracellular Cl− concentration may be higher
also in the adult brain, which has been demonstrated for the
axon initial segment of cortical neurons (Szabadics et al., 2006;
Khirug et al., 2008) and certain types of neurons in amygdala
(Martina et al., 2001) and substantia nigra (Gulacsi et al., 2003), as
well as in gonadotropin-releasing hormone neurons (Moenter and
DeFazio, 2005) and in presynaptic terminals (Haage et al., 2002).
Interestingly, estradiol was one factor that increased the activ-
ity of NKCC1 under normal physiological conditions and thus
increased the intracellular Cl− concentration (Nakamura et al.,
2004; Galanopoulou, 2008). Intriguingly, estradiol dose depen-
dently increased the mood provoking effect of progestagens in
women (Bjorn et al., 2003), and negative mood effects in women
with PMDD/PMS (Dhar and Murphy, 1990).
Finally, would it be possible to explain the inverted bell shaped
relationship between GABAA-receptor active steroid concentra-
tions and symptoms that has been reported from clinical studies?
The report of Prescott et al. (2006) suggested that at a slightly
more positive Cl− equilibrium potential, a moderate increase in
GABAergic activity gave an increased excitation, whereas a larger
GABAergic activity gave the opposite effect. However, whether an
altered intracellular Cl− concentration in adulthood may explain
the paradoxical effect of GABAA-receptor modulators remains to
be proven.
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THE ROLE OF NEUROSTEROIDS IN BEHAVIORAL DISORDERS
A number of review articles have discussed the important role
of neurosteroids in treating behavioral disorders by interacting
with the GABAA-receptor (Majewska, 1992; Reddy and Kulkarni,
2000; Zorumski et al., 2000; Rupprecht et al., 2001). There are
a few obstacles preventing the clinical use of endogenous neu-
rosteroids. First of all, naturally occurring neurosteroids such as
allopregnanolone have low bioavailability because they are rapidly
inactivated and eliminated by glucoronide or sulfate conjuga-
tion at the 3α-hydroxy group. The second obstacle is that the
3α-hydroxy group of allopregnanolone may undergo oxidation
to a ketone, restoring its activity at nuclear hormone receptors
(Rupprecht et al., 1993). Ganaxalone (3α-hydroxy-3β-methyl-5α-
pregnane-20-one), the 3β-methyl analog of allopregnanolone, is
an example of synthetic neurosteroid that overcomes these limi-
tations (Carter et al., 1997). Like allopregnanolone, ganaxalone is
a positive allosteric modulator of GABAA-receptor (Carter et al.,
1997).
Neurosteroids modulate anxiety and stress level. After an acute
stress stimulus, release of progesterone, pregnenolone, allopreg-
nanolone, and 3α5α-THDOC occur in the blood circulation
(Purdy et al., 1992; Barbaccia et al., 1998; Serra et al., 2000). Allo-
pregnanolone and 3α5α-THDOC have potent anxiolytic activity
in several animal anxiety models (Crawley et al., 1986; Bitran
et al., 1995; Wieland et al., 1995; Reddy and Kulkarni, 2000).
However, the anxiolytic effect of allopregnanolone has not been
shown in human (Wihlback et al., 2006). Recent reports indicated
that allopregnanolone can induce aggression and anxiety at low
concentrations (Fish et al., 2001; Gulinello et al., 2001; Miczek
et al., 2003). Allopregnanolone and cortisol levels are increased
during the examination of PhD students (Droogleever Fortuyn
et al., 2004). Therefore, it is suggested that allopregnanolone has
biphasic effects in certain individuals (Miczek et al., 2003). At low
doses it has an adverse, anxiogenic effect. This effect decreases with
increasing doses of allopregnanolone and the beneﬁcial and calm-
ing property occurs (Beauchamp et al., 2000; Fish et al., 2001).
A major concern with potential new anxiolytics is whether they
suffer the same drawbacks as classical benzodiazepines. Using the
elevated plus-maze paradigm for assessing the anxiolytic activity,
selective effects of neurosteroids have been reported which differ
from diazepam (Rodgers and Johnson, 1998). Synthetic deriv-
ative Co 2-6749 30, which retains a 3β-triﬂuoromethyl group
that should block metabolism and enhance oral bioavailability,
is selected for clinical development because there is a large sep-
aration between anxiolytic effects and side effects (Gasior et al.,
1999; Vanover et al., 2000). Women with PMDD show often dif-
ﬁculties in concentration and develop fatigue during the luteal
phase of the menstrual cycle, which is associated with high cir-
culating levels of allopregnanolone (Sundstro and Backstrom,
1999).
Enzymes involving the production of allopregnanolone are
present in the hippocampus (Compagnone and Mellon, 2000).
Using the Morris water maze paradigm, allopregnanolone was
found to inhibit learning (Johansson et al., 2002). Antagonist
neurosteroid 3β, 20β-dihydroxy-5α-pregnane (UC1011), reduced
the negative effect of allopregnanolone on learning in the Morris
water maze (Turkmen et al., 2004). PS infused into the basal
magnocellular nucleus enhanced memory performance, whereas
allopregnanolone disrupted memory (Mayo et al., 1993). Preg-
nenolone, DHEA, and DHEAS increased memory when injected
systemically, centrally or into the amygdala (Flood et al., 1988,
1992; Wolkowitz et al., 1995). There was evidence that the con-
centrations of DHEA and DHEAS decreased in patients suffering
fromAD (Sunderland et al., 1989;Nasman et al., 1991;Hillen et al.,
2000). It is promising that certain neurosteroids should be further
explored in the context of prevention and treatment of Alzheimer’s
disease and mild cognitive impairment.
GABA-STEROIDS AND COGNITIVE FUNCTIONS
Chronic stress, stress-steroids, and sex steroids are linked to the
development of dementia (Shumaker et al., 2003; Lupien et al.,
2005; Sandstrom et al., 2005). In women taking postmenopausal
hormone therapy by administration of medroxyprogesterone, a
GABA-steroid precursor, the risk for dementia, and AD doubled
after 5 years of treatment (Shumaker et al., 2003). Medroxyprog-
esterone can induce anesthesia by acting on the GABAA-receptor
(Meyerson, 1967). On the other hand, estrogen has been claimed
to protect against dementia (Henderson et al., 1994). This was,
however, not conﬁrmed in the large Women’s Health Initiative
(WHI) study but estrogen by itself did not increase the risk to
develop dementia (Shumaker et al., 2004). Hormone therapy with
medroxyprogesterone resembles the exposure to stress-steroids
during chronic stress. GABAA-receptor agonists are known to
impair memory. Allopregnanolone can inhibit learning in rats
tested in Morris water maze, an accepted test model for learning
and memory (Johansson et al., 2002). It is well-known that most
GABAA-receptor agonists, e.g., benzodiazepines (Barker et al.,
2004), barbiturates (Mohammed et al., 1987), and alcohol (Saun-
ders et al., 1991; Vincze et al., 2007) impair memory and learning
and increase the risk for permanent damages, although the risk
with low and moderate alcohol consumption is under debate
(Solfrizzi et al., 2007).
The brain and serum concentrations of GABA-steroids vary
with the production of adrenals, ovaries, and testicles (Purdy
et al., 1991; Wang et al., 1996; Bixo et al., 1997; Luisi et al.,
2000). Interestingly, classical stress hormones, cortisol, and cor-
ticosterone, metabolized in a similar way and allotetrahydrocor-
tisol (Allo-THF, 3α-hydroxy-5α-cortisol) interacts also with the
GABAA-receptor (Celotti et al., 1992). Allo-THF enhances the
inhibitory effect of allopregnanolone and has synergic effect on
neuronal inhibition together with allopregnanolone (Stromberg
et al., 2005). That is why neurons are exposed to a stronger
inhibition during acute and chronic stress. During acute stress,
allopregnanolone and THDOC increase in the brain of normal
animals. In animals subjected to chronic long-term stress, allo-
pregnanolone concentrations decreased in cortex at rest. However,
a larger increase of allopregnanolone was observed in cortex
after acute stress in this group of animals than normal con-
trols (Serra et al., 2000). Patients with AD show an increased
glucocorticoid production compared to healthy elderly control
subjects. In addition, an increased 5α-reduction was seen in
patients with AD. Thus an increased glucocorticoid production
can be regarded as an early feature of AD since an enhanced
production of 5α-reduced metabolites of cortisol was established
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(Rasmuson et al., 2001). 3α-OH-5α-reduced metabolites of cor-
tisol interact with the GABAA-receptor and enhance the effect
of GABA-steroids on the GABAA-receptor (Stromberg et al.,
2005).
Chronic stress can impair memory (de Quervain et al., 1998).
Memory impairment is permanent in persons with a chroni-
cally elevated adrenal production of GABA-steroids (Lupien et al.,
2005). Memory impairment was also reported in chronic stress
syndromes, so called“burn-out syndrome.”“Burn-out syndrome”
occurs frequent in patients with AD. The production of corti-
sol and GABA-steroids increased in parallel during stress (Purdy
et al., 1991; Serra et al., 2003; Droogleever Fortuyn et al., 2004).
During chronic stress, long-term exposure to GABAA-receptor
agonist results in similar changes after prolonged exposure to
benzodiazepine and alcohol. Long-term and enhanced activation
of the GABAA-receptor is an important factor in of memory
impairment during stress. The response of cortisol and GABA-
steroids to adrenal stimulation was similar in patients with AD
as chronically stressed animals (Nasman et al., 1991, 1996).
Patients with mild Alzheimer’s disease have a high and non-
suppressible production of cortisol and GABA-steroids (Nasman
et al., 1995).
After long-term exposure to GABA-steroids, down-regulation
of the GABAA-receptor is expected (Yu and Ticku, 1995b; Barnes,
1996). A malfunctioned GABAA-receptor can be an important
factor in the pathogenesis of stress-induced depression, “burn-
out” syndrome and sex-steroid related depression (Drugan et al.,
1989; Wihlback et al., 2006). The down-regulation occurs at dif-
ferent levels in a time dependent manner: (i) desensitization; (ii)
receptor internalization; (iii) receptor subunit degradation; (iv)
altered expression of receptor mRNA (Barnes, 1996). Exposure to
an agonist of the GABAA-receptor may cause changes in recep-
tor mRNA and induce changes of the GABAA-receptor subunit
composition (Smith et al., 1998). In women with PMDD, reduced
benzodiazepine, ethanol, and GABA-steroid sensitivities occur in
the luteal phase, but not in the follicular phase of the men-
strual cycle (Sundstrom et al., 1997, 1998; Nyberg et al., 2004).
In rodents, repeated administrations of GABA-steroids caused
tolerance development (Birzniece et al., 2006a) in terms of GABA-
steroid-induced inhibition on learning (Turkmen et al., 2006).
It is well-known that prolonged exposure to allopregnanolone
altered the function of α4 subunit and α1 subunit (Smith et al.,
1998). In fact, the α4β2γ2 receptor is less sensitive to steroid
modulation than the α1β2γ2 receptor (Belelli et al., 2002). In
an earlier study on tolerance development in rats, acute tol-
erance against allopregnanolone-induced anesthesia developed
after 90min of exposure and change in GABAA-receptor α4-
subunit expression was observed in thalamus (Birzniece et al.,
2006a).
ALLOPREGNANOLONE AND SUPPRESSED HPA AXIS STRESS
RESPONSES IN LATE PREGNANCY OF RAT
In late pregnancy, hypothalamo-pituitary–adrenal (HPA) axis
responses to stressful stimuli are suppressed (Brunton and Rus-
sell, 2003). Up-regulated opioid peptide produced by nucleus
tractus solitarii (NTS) neurons acts presynaptically on noradren-
ergic terminals in the paraventricular nucleus (PVN) to inhibit
noradrenaline release in response to interleukin-1β (IL-1β) in late
pregnancy (Brunton et al., 2009). Allopregnanolone signals the
pregnancy status of the animal to the brain and stimulates opi-
oid production in the brainstem. Allopregnanolone also act via
GABAA-receptors to enhance GABA action in the PVN. In rat,
allopregnanolone concentration increase greatly in both the cir-
culation and the brain in pregnancy and reach a peak on day
19–20 of pregnancy (Concas et al., 1998; Brunton et al., 2009).
Parvocellular corticotropin-releasing hormone (CRH) neurons in
the PVN are under direct inhibitory GABAergic control (Mik-
los and Kovacs, 2002). 5α-reductase activity is increased in the
hypothalamus in late pregnancy (Brunton et al., 2009), suggest-
ing that the capacity to produce allopregnanolone is increased in
pregnancy. Allopregnanolone may act locally to enhance GABA
action in the PVN or on inputs to the CRH neurons to attenuate
HPA axis responses to stress in late pregnancy. The importance
of allopregnanolone to inhibit HPA axis responses to stress in
later pregnancy has been tested by blocking its production using a
5αR inhibitor, ﬁnasteride (FIN). Blocking allopregnanolone gen-
eration with ﬁnasteride (FIN) at a dose shown to reduce brain
allopregnanolone content by up to 90% (Concas et al., 1998),
substantially restores HPA axis responses to systemically adminis-
tered IL-1β in late pregnant rats (Brunton et al., 2009). AP appears
to depend upon the actions of endogenous opioids to exert its
suppressive effects on HPA axis activity (Brunton et al., 2009).
Allopregnanolone induces opioid tone (as revealed by naloxone
treatment) over ACTH responses to immune challenge in vir-
gin rats (Brunton et al., 2009). Induction of inhibitory opioid
tone over HPA axis responses to IL-1β by AP treatment occurs
within 20 h, consistent with the rapid increase in pENK-A mRNA
expression in the NTS that has been seen after IL-1β treatment
(Engstrom et al., 2003). The mechanism by which AP upregulates
opioid expression in the NTS is not clear. However, interac-
tion with GABAA-receptors is a possibility (Blyth et al., 2000)
as has been described for CRH and vasopressin gene expres-
sion in the PVN (Bali and Kovacs, 2003) and for hypothala-
mic oxytocin gene expression at the end of pregnancy (Blyth
et al., 2000). It is possible that allopregnanolone-induced opi-
oid tone represents a global mechanism through which HPA
axis responses to other stressful stimuli are restrained in late
pregnancy. This pregnancy adaptation is expected to protect the
fetuses from adverse early life programming by maternal glu-
cocorticoids, although this protection is obviously incomplete
(Brunton and Russell, 2010, 2011). Withdrawal of these mech-
anisms or failure to maintain them appropriately might pre-
dispose the fetuses to disease in later life (Welberg and Seckl,
2001).
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